Results 281 to 290 of about 672,953 (296)

Phenotyping vasodilator responsiveness in idiopathic pulmonary arterial hypertension: any role for the cardiopulmonary exercise test? [PDF]

ERJ Open Res
Sivasubramaniam G, Baccelli A, Haji G, Lo Giudice F, Weaver C, Howard L, Davies R.   +6 more
europepmc   +1 more source

Feasibility and Safety of Transfemoral Aortic Valve Replacement Using Local Anesthesia in the Catheterization Suite Versus General Anesthesia in the Operation Theater

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background For over a decade, transfemoral transcatheter aortic valve replacements (TF‐TAVR) have been performed at the University Hospital of Nancy. A minimalistic approach to TF‐TAVR, conducted without general anesthesia and entirely percutaneously in a catheterization suite (simplified approach), has been reported to be as safe and ...
Guillaume Abadié, Pierre Adrien Metzdorf, Giuseppe Lauria, Jeanne Varlot, Mazen Elfarra, Florian Eggenspieler, Juan‐Pablo Maureira, Batric Popovic, Edoardo Camenzind   +8 more
wiley   +1 more source

Microbiome-Immune Interaction in Pulmonary Arterial Hypertension: What Have We Missed? [PDF]

Research (Wash D C)
Zhou X, Tian W, Gu S, Rabinovitch M, Nicolls MR, Snyder MP.   +5 more
europepmc   +1 more source

Three‐Cusp View Orientation in TAVI: Evaluating LOA Versus Non‐LOA Impact on Outcomes With Contemporary Valve Prostheses

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Optimal projection views during transcatheter aortic valve implantation (TAVI) procedures are critical for procedural success and patient outcomes. Aims This study investigated the influence of 3‐cusp view orientation—line of alignment (LOA) versus non‐LOA—on procedural outcomes in patients undergoing TAVI with contemporary ...
Rim Kasem Ali Sliman, Amnon Eitan, Keren Zisman, Yuval Avidan, Amir Aker, Hussein Sliman   +5 more
wiley   +1 more source

Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study. [PDF]

Am J Respir Crit Care Med
Rothman AMK, Villar SS, Middleton J, Roussakis AA, Varian F, Zafar H, Law M, Apperley J, Bartelink IH, Said MM, Delgado-SanMartin JA, Kiely DG, Howard L, Toshner M, Wort SJ, Wilkins MR.   +15 more
europepmc   +1 more source

Drug‐Coated Balloon‐Based Versus Drug‐Eluting Stent‐Only Treatment for Large Vessel Coronary Artery Disease

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Drug‐coated balloon (DCB) treatment has shown outcomes comparable to drug‐eluting stent (DES) in small vessel coronary disease. However, evidence for its application in large vessel coronary artery disease (CAD) remains limited. Aims This study evaluated the clinical impact of DCB‐based percutaneous coronary intervention (PCI) in ...
Eun‐Seok Shin, Mi Hee Jang, Sunwon Kim, Dong Oh Kang, Ae‐Young Her, Chang‐Bae Sohn   +5 more
wiley   +1 more source

Location of Care Delivery for Pulmonary Arterial Hypertension in the United States. [PDF]

Am J Respir Crit Care Med
Leary PJ, Le RJ, Panjabi S, Hartney J, Goyal A, Ward C, Mukherjee D, Hatton N, Rayner SG, Germack HD, Ryan JJ.   +10 more
europepmc   +1 more source

Pterostilbene mitigates experimental pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition. [PDF]

Front Pharmacol
Wang J, Zhang Y, Liu J, Jiang F, Cui X, Lu W.   +5 more
europepmc   +1 more source

Plain language summary: oral treprostinil (Orenitram) for the treatment of pulmonary arterial hypertension (PAH). [PDF]

Future Cardiol
Davis BNJ, Suplicki T, Patzlaff N, White J.   +3 more
europepmc   +1 more source